Questions and answers in chronic urticaria: where do we stand and where do we go?

被引:18
作者
Maurer, M. [1 ]
Church, M. K. [1 ]
Marsland, A. M. [2 ]
Sussman, G. [3 ,4 ]
Siebenhaar, F. [1 ]
Vestergaard, C. [5 ]
Broom, B. [6 ]
机构
[1] Charite Univ Med Berlin, Allergie Ctr Charite, Dept Dermatol & Allergy, Berlin, Germany
[2] Univ Manchester, Manchester Acad Hlth Sci Ctr, Salford Royal NHS Fdn Trust, Manchester, Lancs, England
[3] St Michaels Hosp, Div Allergy & Clin Immunol, Toronto, ON, Canada
[4] Univ Toronto, Toronto, ON, Canada
[5] Aarhus Univ Hosp, Dept Dermatol & Venereol, Aarhus, Denmark
[6] Auckland City Hosp, Dept Immunol, Auckland, New Zealand
关键词
QUALITY-OF-LIFE; OMALIZUMAB; GUIDELINES; MANAGEMENT; CARE; CSU;
D O I
10.1111/jdv.13695
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
This supplement reports proceedings of the second international Global Urticaria Forum, which was held in Berlin, Germany in November 2015. In 2011, a report of the GA(2)LEN task force on urticaria outlined important and unanswered questions in chronic urticaria (CU). These included, but were not limited to, questions on the epidemiology and course of chronic spontaneous urticaria (CSU) [also called chronic idiopathic urticaria (CIU)], the resources allocated for the diagnosis and treatment of CSU, whether patients with angioedema as an isolated symptom can be regarded as a subgroup of CSU, and the efficacy and long-term safety of therapies. Many of these questions have been addressed by recent studies. Some of the answers obtained raise new questions. Here, we summarize some of the key insights on CU obtained over recent years, and we discuss old and new unmet needs and how to address them with future studies. We need to analyze the influence of recent advances in understanding of the burden of CU on patients and society, disease management and the CU patient journey. Our increased understanding of urticarial pathophysiology and consideration of the patient as a whole will need to be translated to better treatment algorithms and protocols. Actions to address these challenges include the 5th International Consensus Meeting on Urticaria, which will take place later this year. The formation of a global network of Urticaria Centers of Reference and Excellence over the next few years has also been proposed, with the aim of providing consistent excellence in urticaria management and a clear referral route, furthering knowledge of urticaria through additional research and educating/promoting awareness of urticaria.
引用
收藏
页码:7 / 15
页数:9
相关论文
共 50 条
[31]   Intrapleural Fibrinolytic Therapy in Empyema Thoracis: Where are we now and where do we go from here? [J].
Mathew, Joseph L. .
INDIAN JOURNAL OF PEDIATRICS, 2019, 86 (12) :1081-1082
[32]   Refractory Chylothorax: Where Do We Go Now? [J].
Bielsa, Silvia ;
Pardina, Marina .
CURRENT PULMONOLOGY REPORTS, 2019, 8 (02) :60-67
[33]   Irreversible Electroporation in Interventional Oncology: Where We Stand and Where We Go [J].
Savic, L. J. ;
Chapiro, J. ;
Hamm, B. ;
Gebauer, B. ;
Collettini, F. .
ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN, 2016, 188 (08) :735-745
[34]   Cancer screening in the aging population: Where do we stand and what can we do? [J].
Cao, Wei ;
Chen, Wanqing .
JOURNAL OF THE NATIONAL CANCER CENTER, 2022, 2 (03) :127-129
[35]   Education and training in geriatrics in the 21st century - where do we come from - where do we go? [J].
Roller, R. E. ;
Petermans, J. .
EUROPEAN GERIATRIC MEDICINE, 2015, 6 (03) :205-207
[36]   Antihypertensive therapy in acute ischemic stroke: where do we stand? [J].
Georgianou, Eleni ;
Georgianos, Panagiotis I. ;
Petidis, Konstantinos ;
Athyros, Vasilios G. ;
Sarafidis, Pantelis A. ;
Karagiannis, Asterios .
JOURNAL OF HUMAN HYPERTENSION, 2018, 32 (12) :799-807
[37]   Guidelines Recommendations on the Treatment of Tricuspid Regurgitation. Where Are We and Where Do We Go With Transcatheter Valve Intervention [J].
Vahanian, Alec ;
Brochet, Eric ;
Juliard, Jean-Michel .
FRONTIERS IN CARDIOVASCULAR MEDICINE, 2018, 5
[38]   Hepatitis C Virus-Where are We Now and Where Do We Go From Here? [J].
Trooskin, Stacey ;
Jhaveri, Ravi .
CLINICAL THERAPEUTICS, 2020, 42 (08) :1425-1432
[39]   Anticoagulation: where we are and where we need to go [J].
Barnes, Geoffrey D. ;
Froehlich, James B. .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2009, 28 (02) :220-223
[40]   Trends in Colposcopy Volume: Where Do We Go From Here? [J].
Landers, Emily E. ;
Erickson, Britt K. ;
Bae, Sejong ;
Huh, Warner K. .
JOURNAL OF LOWER GENITAL TRACT DISEASE, 2016, 20 (04) :292-295